Novo-Nordisk A/S's US stock fell nearly 20% at the start of trading, while competitor Eli Lilly and Co rose over 6%, and Viking Therapeutics increased by over 4%.

Breakings · Dec 20 22:35

Novo-Nordisk A/S's U.S. stock fell nearly 20% in early trading due to disappointing trial results of the weight loss drug CagriSema, while competitor Eli Lilly and Co rose over 6%, and Viking Therapeutics increased by over 4%.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

诺和诺德美股盘初大跌近20%，竞争对手礼来涨超6%，Viking Therapeutics涨超4%

Novo-Nordisk A/S's US stock fell nearly 20% at the start of trading, while competitor Eli Lilly and Co rose over 6%, and Viking Therapeutics increased by over 4%.

Risk Disclaimer

Statement